Applications

Near-Term Applications for NADA’s Whole Brain Computer Interface

Noninvasive BCI Research

Many laboratories are exploring Brain-Computer Interfaces with both noninvasive and invasive technologies. Meta AI, for example, has recently demonstrated the ability to decode a participant’s typing intentions with reasonable accuracy with 300-channel MEG (Lévy et al., 2025). Although these authors claim superior performance for MEG versus EEG, their EEG system was limited to 64 channels. Now classical analyses on first principles show that, if head tissue conductivity is specified carefully, MEG and EEG are roughly equivalent and limited mainly by channel count (Malmivuo, 2012; Ryynanen, Hyttinen, Laarne, & Malmivuo, 2004). A replication of this experiment with a 280-channel HDEEG would allow a direct comparison. Including individual head modeling with source localization to the cortical surface will achieve more detailed classification of levels of language process, rather than being limited to the motor actions of typing.

Comparison of Invasive versus Noninvasive BCI

It is often assumed that invasive recordings provide more information, particularly if a large number of electrodes is included, such as in the Neuralink and Paradromics approaches. However, the distributed nature of brain representations suggests that a Whole Brain-Computer Interface (WBCI) may achieve higher information bandwidth, a question that could be easily answered with a shared experimental protocol.

Neurosurgical Planning

Although BCI systems are often justified to allow communication from a patient with ALS or other locked-in syndrome, these are fairly rare cases. Neurosurgery, however, is a much wider application, and advances in both emulation and functional brain mapping may have wide market adoption. FDA and other regulatory clearances are essential.

Dementia Risk Prediction and Prevention

With the aging of the population in many industrial countries, dementia is a massive health problem. Advances in WBCI will allow not only improved precision in neurological diagnosis, but new options for noninvasive neuromodulation (see neurosom.net).

From Breakthroughs to Buildout: NADA’s Milestones

Our journey blends deep neuroscience with cutting-edge AI, backed by SBIR grants, FDA-clearance pathways, and proprietary technology. These milestones mark our progress toward building the world’s first functional, whole-brain interface—and position NADA for accelerated growth as we approach Series A.